Gut Microbes Serve as Indicators of Colorectal Cancer

The abundance of specific types of bacteria in the guts of patients with colorectal cancer could lead to the development of a noninvasive, sensitive clinical diagnostic test for colorectal cancer.
Current screening methods for colorectal cancer include the invasive colonoscopy or less invasive tests, such as a home-based fecal occult blood tests. Although these screening methods prove helpful, they each have shortcomings.
In a study published in Gut, investigators sought to examine the use of gut microbes as indicators of the disease.
“A number of studies have shown an association between fecal microbes and colorectal cancer; however, there is limited agreement in the types of microbes reported,” said first author Dr Manasi Shah. “I was interested in finding a microbial marker for the disease. One way to do this is by carrying out a single-institution study, but this takes a long time for sample collection, involves sequencing the microbes’ DNA, and is expensive.”
Dr Shah noticed that some published research provided the means necessary for accessing the raw microbial DNA sequencing data of the samples.
“How great it would be, I thought, if I could leverage existing raw data across multiple cohorts and come up with a generalizable marker for the disease,” Dr Shah said.
She collaborated with senior author Dr Emily Hollister from the Texas Children’s Microbiome Center, to learn the necessary tools to reprocess microbial sequence data from its original form.
“Manasi had the interest, and we had the expertise,” Dr Hollister said. “In our center, we had been planning to compare a series of different statistical tools to analyze large amounts of microbiome data.”
The authors reanalyzed raw bacterial DNA sequence data from several studies. They confirmed previously reported types of bacteria associated with colorectal cancer, and identified other bacteria not previously associated with the cancer.
“In our experience, collecting the raw data from the published studies was an uphill task,” Dr Shah said. “Some studies shared all the sample-associated microbial DNA sequences and clinical data, others only shared partial data or did not share any data at all. After much effort, I was able to gather data from 9 of 12 published studies. This highlights the need for an initiative to encourage investigators to share their data upon publication, which will help wider dissemination and reproducibility in the field.”
An additional challenge in the study were the various technological approaches the different laboratories used to analyze the samples.
“This was an incredibly large, complex multinational study,” said co-author Todd DeSantis. “We saw many differences between medical centers in the way each collected and stored stool samples and in the methods used to process the bacterial DNA in stools. These differences can be problematic for identifying the bacterial strains that proliferate in cancer patients, but our Second Genome KnowledgeBase Team, led by co-author Thomas Weinmaier, found ways to enhance our software platform to address these differences along the way. The findings that emerged from this challenging data set helped validate our platform, and in the process we were able to deliver high-quality insights to advance our collaboration with Dr Hollister.”
The investigators used a variety of statistical tools to uniformly reanalyze large amounts of raw bacterial DNA sequence data from several studies. They confirmed the previously reported types of bacteria associate with the disease and the other bacteria that was not previously associated.
“The fact that even when we combined several different studies we could correctly classify a sample as a colorectal cancer case or control with 80% accuracy solely based on microbial abundances was very encouraging,” Dr Shah said.
Hollister added, “This is a promising first step to develop a noninvasive test that might be used in the detection of colorectal cancer, supplementing colonoscopy or fecal occult blood tests.”
The authors noted that their findings could be adapted to use with other diseases.
“The same strategy could be applied for developing diagnostic tests or therapeutics for other diseases such as inflammatory bowel disease, nonalcoholic steatohepatitis, type 2 diabetes, and Alzheimer’s disease, among others for which the microbiome is currently being investigated,” Dr Shah concluded.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

African Americans can frequently experience barriers in seeking out lifesaving clinical trials for cancer treatments.
The presence of human papillomavirus type 16 antibodies marked an approximately 100-fold increase in risk of throat cancer in white individuals.
Colon cancer may spread to other parts of the body before original tumors are clinically detectable.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.